Yingchang Cai

Yingchang Cai

Auto-generated profile, based on publicly available information

Yingchang Cai

Department of Anorectal Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou 324003, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
YCYingchang Cai
Yingchang Cai
FZFeng Zhao
Feng Zhao
XCXiaofei Cheng
Xiaofei Cheng
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Although immune checkpoint inhibitors (ICIs) have achieved striking clinical efficacy in the subset of CRCs with mismatch repair deficiency/high microsatellite instability (dMMR/MSI-H), the vast majority of patients—those with proficient mismatch repair/microsatellite-stable (pMMR/MSS) tumors—derive little benefit from current immunotherapies. Ferroptosis, an iron-dependent form of regulated cell death driven by lethal accumulation of lipid peroxides, has emerged as a promising antitumor mechanism that can interact with and modulate antitumor immunity. Concurrently, the gut microbiota exerts powerful control over host metabolism and immune tone through microbial community structure and metabolite production; accumulating evidence indicates that microbiota-derived factors can either sensitize tumors to ferroptosis (for example, via short-chain fatty acids) or confer resistance (for example, indole-3-acrylic acid produced by Peptostreptococcus anaerobius acting through the AHR→ALDH1A3→FSP1/CoQ axis). In this review we synthesize mechanistic data linking microbial ecology, iron and lipid metabolism, and immune regulation to ferroptotic vulnerability in CRC. We discuss translational strategies to exploit this “microbiota–ferroptosis” axis—including precision microbiome modulation, dietary interventions, pharmacologic ferroptosis inducers, and tumor-targeted delivery systems—and we outline biomarker frameworks and trial designs to evaluate combinations with ICIs. We also highlight major challenges, such as interindividual microbiome variability, potential collateral harm to ferroptosis-sensitive immune cells, adaptive antioxidant compensation (e.g., NRF2/FSP1 activation), and safety/regulatory issues for live biotherapeutics. In summary, this review highlights that targeting the microbiota-ferroptosis axis may represent a rational and potentially transformative approach to reprogramming the tumor microenvironment and overcoming immune checkpoint resistance in pMMR/MSS colorectal cancer; however, further research is essential to validate this concept and address existing challenges.

1 January 2025 in American Journal of Cancer Research
Verified
Journal Article
Closed access
JGJiang Gong
Jiang Gong
BXBinsong Xia
Binsong Xia
LQLei Qian
Lei Qian
YCYingchang Cai
Yingchang Cai
This study investigates CCDC78 as a potential prognostic biomarker in colorectal cancer (CRC), incorporating both clinical correlation and functional validation. Analysis of 135 paired tumor and adjacent tissues revealed significantly elevated CCDC78 expression in tumor tissues (P<0.001), and higher expression levels were associated with markedly lower 5-year survival rates (P=0.001). Time-dependent ROC curves demonstrated robust prognostic performance at 12, 36, and 60 months (AUCs of 0.85, 0.84, and 0.82, respectively). In vitro assays showed that CCDC78 overexpression significantly enhanced cell proliferation, migration, and invasion (P<0.05), whereas siRNA-mediated knockdown suppressed these phenotypes and increased apoptosis (P<0.01). Cox regression analyses identified CCDC78 as an independent prognostic factor (P=0.02). Notably, despite similar baseline expression across CRC cell lines, SW480 cells were more sensitive to knockdown, while HCT116 cells more strongly recapitulated the overexpression phenotype. TCGA pan-cancer analysis showed upregulated CCDC78 in various tumors, including CRC, adrenocortical carcinoma (ACC), bladder cancer (BLCA), and kidney renal clear cell carcinoma (KIRC), reinforcing its broad oncogenic relevance. Correlation analyses linked high CCDC78 expression to older age, poor tumor differentiation, advanced TNM stage, lymph node metastasis, and distant metastasis. Immune profiling revealed negative associations with 11 immune cell types but a positive correlation with NK CD56 bright cells. Gene set enrichment analysis (GSEA) implicated CCDC78 in interferon-JAK-STAT, RIG-I/NFκB, and WNT signaling pathways. Altogether, these findings suggest that CCDC78 promotes CRC progression through enhancing tumor cell aggressiveness and modulating the immune microenvironment, underscoring its potential as a prognostic biomarker and therapeutic target.